- Home
- PCM vs CALC Comparison
PCM vs CALC Comparison
Compare PCM & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCM | CALC |
|---|---|---|
| Founded | 1993 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.0M | 88.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PCM | CALC |
|---|---|---|
| Price | $6.06 | $6.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 29.1K | ★ 93.6K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 11.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.88 | $1.42 |
| 52 Week High | $10.20 | $7.20 |
Technical Indicators
Market Signals| Indicator | PCM | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 33.81 | 68.87 |
| Support Level | $6.09 | $5.90 |
| Resistance Level | $6.15 | $6.40 |
| Average True Range (ATR) | 0.06 | 0.59 |
| MACD | -0.01 | 0.13 |
| Stochastic Oscillator | 4.35 | 64.63 |
Price Performance
Historical ComparisonAbout PCM PCM Fund Inc.
Pcm Fund Inc is a closed-end investment management company. Its investment objective is to seek current income as a primary focus and also capital appreciation. The Fund invests in agency-guaranteed mortgage-backed securities, private-label mortgage-backed securities, high-yield corporate debt securities, and commercial mortgage-backed securities.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.